RecruitingNot applicableNCT05978128

Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible Participants

This clinical trial assesses the use of advocates and supporters of breast and lung cancer screening to increase lung cancer screening rates amongst eligible participants. Imaging-based cancer screening is utilized with variable frequency. Breast cancer screening with mammography has been widely accepted and is commonly used among eligible women. Lung screening with computed tomography scans is poorly used, despite the potential to decrease deaths from lung cancer. There are many reasons lung screening isn't being used when compared to breast screening, such as smoking stigma and fear, along with a lack of awareness of lung screening. By conducting this trial, researchers want to assess the effectiveness of advocates and supporters of breast and lung screening, and to learn about the psychological barriers to cancer screening, identifying those that are unique to lung screening.

Checked against the public recordLast updated Nov 10, 2025 · Source: ClinicalTrials.gov

StatusRecruiting
PhaseNot applicable
U.S. locations1
SponsorJonsson Comprehensive Cancer Center
01
Study overview

What this study is about

Purpose
Screening
Study type
Interventional
Phase
Not applicable
Sponsor
Jonsson Comprehensive Cancer Center
Interventions being studied
Behavioral: Health Education; Other: Health Promotion and Education; Behavioral: Patient Navigation; Other: Survey Administration
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: * Age: * Breast screening \> 40 * Lung screening 50-80 * Male (M) or Female (F) * Current, former, or never smokers * Close family or friend with smoking history (in or out of state) Exclusion Criteria: * Age: * Breast screening \< 40 * Lung screening \< 50 or \> 80 * Persons who had previously received a diagnosis of lung cancer, had hemoptysis, or had an unexplained weight loss of more than 6.8 kg (15 lb) in the preceding year will also be excluded * Persons with an active cancer

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • UCLA / Jonsson Comprehensive Cancer CenterLos Angeles, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 10, 2025. Always confirm current availability with the study team.

View original record ↗